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Acute myeloid leukemia (AML) is the most common acute leukemia in American adults and portends a poor prognosis if
untreated. Commonly, AML presents with symptoms related to concurrent leukopenia, anemia, or thrombocytopenia; however,
due to its ability to aﬀect many organ systems in the body, AML can have a highly varied clinical presentation. One such
presentation is myocarditis, which is a rarely reported manifestation of AML. Myocarditis can have a varied clinical picture and
often requires exclusion of other causes of cardiac dysfunction. Sweet syndrome, also known as acute febrile neutrophilic
dermatosis, is another presentation of AML; however, it is more commonly associated with AML than cardiac involvement. Sweet
syndrome can occur in patients with an already established malignancy or can occur de novo in a patient with previously
undiagnosed cancer and, interestingly, can also be accompanied by extracutaneous manifestations, one of which is myocarditis.
Herein, we report a case of a 45-year-old male with a history of obesity and depression who presented with chest pain, a tender and
diﬀuse rash, and pancytopenia. Heart catheterization performed at outside institution was negative for coronary artery disease.
Cardiac MRI images were compatible with myocarditis. Dermal biopsy of the rash was consistent with sweet syndrome. Peripheral
blood ﬂow cytometry and bone marrow biopsy conﬁrmed the diagnosis of AML. He was treated with an induction chemotherapy
regimen of 7 days of cytarabine and 3 days of daunorubicin with resolution of his chest pain and skin lesions. The patient had
persistent leukemia cells on day 14 postinduction bone marrow biopsy and was treated with high-dose cytarabine reinduction
treatment. Bone marrow biopsy with count recovery after reinduction therapy revealed complete response (CR).

1. Introduction
Acute myeloid leukemia (AML) is the most common acute
leukemia in American adults, accounting for 80% of all
leukemia and totaling to a yearly incidence of 20,000 cases in
the US [1]. AML is known to have a highly varied clinical
presentation due to its ability to inﬁltrate and aﬀect many
organ systems in the body. One such association is a clinical
entity known as sweet syndrome, which is also known as
acute febrile neutrophilic dermatosis. Sweet syndrome is
characterized by discrete, tender skin lesions with a heavy
inﬁltrate of mature neutrophils and may be accompanied by
extracutaneous disease. In up to 20% of cases, sweet syndrome is associated with malignancy with AML being the

most frequent [2]. It can occur in patients with established
diagnosis of malignancy as a paraneoplastic disorder, or it
could occur prior to a formal diagnosis of malignancy.
Furthermore, one potential extracutaneous manifestation of
sweet syndrome is myocarditis, which is also a rare presentation of AML. Autopsies of patients who expired due to
AML have shown that up to 37.1% have cardiac leukemic
inﬁltrates [3]. However, myocarditis is a very uncommon
manifestation of this, with our literature review producing
only three case reports describing this association with AML.
Our literature review also produced only four cases of patients with concurrent sweet syndrome and myocarditis.
Here, we present a patient who presented with chest pain
and increased cardiac enzymes secondary to myocarditis, a
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rash that was biopsy proven to be sweet syndrome, and
pancytopenia secondary to new diagnosis of AML.

2. Case Presentation
A 45-year-old male with a past medical history of hypertension and depression presented to an outside hospital’s
emergency department with a primary complaint of chest
pain of one day duration. He was in his usual state of health
prior to the onset of the chest pain. This chest pain was
progressively worsening, substernal, radiated to his back,
and was unaﬀected by position. On presentation, he was
found to have elevated troponins and was provided nitroglycerin, which relieved his chest pain. Initial electrocardiogram (ECG) was without any ST elevations. He was
subsequently taken for left heart catheterization and found
to have nonobstructive coronary artery disease. He was
discharged to home on metoprolol, aspirin, statin, and a
proton pump inhibitor. He was also discharged on indomethacin due to suspicion of myocarditis at that time. After
discharge, however, his chest pain continued to worsen.
Around that time, he also started to notice a painful dark
rash on his legs.
The worsening chest pain and new onset rash prompted
him to return to the ED about ﬁve days after his recent
discharge, and he was subsequently transferred to our
hospital’s ED. On presentation, he further endorsed strong
feelings of fatigue over the prior few days and was admitted
to several nights of drenching sweats. He also had subjective
fevers and chills. He denied any recent shortness of breath,
documented fevers, changes in weight, or sensation of heart
palpitations. The patient was afebrile with a heart rate of 76,
blood pressure of 129/63, a respiratory rate of 18, and 99%
oxygen saturation in room air. On physical exam, the patient
was an obese male in no acute distress. He was observed to
have a linear grouping of well-circumscribed tender papules
with a deep red to purple base on his left thigh with the
largest lesion being about six centimeters. He also had
similar smaller lesions located on his right forearm, left
upper arm, and left cheek. Cardiopulmonary exam was
normal with clear lungs in all ﬁelds and no abnormal heart
sounds or peripheral edema. The rest of systemic examination was normal.
Initial laboratory evaluation revealed elevated highsensitivity troponins at 958 ng/L (<19 ng/L) and elevated
NT-proBNP at 1104 pg/mL (<449 pg/mL). Repeat highsensitivity troponin level 2 hours later was stable at 899 ng/L.
His initial ECG showed no acute changes (Figure 1), and a
bedside echocardiogram showed a preserved ejection
fraction.
Continued workup revealed a white blood cell count of
2.20 k/µL (3.7–10.3 k/uL), an absolute neutrophil population
of 0.75 k/µL, 21% peripheral blasts, hemoglobin of 8.7 g/dL
(13.7–17.5 g/dL), and a platelet count of 116 k/µL (155–369 k/
uL). This pancytopenia with peripheral blasts and an elevated
LDH of 335 U/L (116–250 U/L) raised strong suspicion for
acute leukemia. His uric acid, creatinine, and liver function
tests were all within normal limits. Peripheral blood smear
conﬁrmed pancytopenia with circulating blasts. Peripheral
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blood ﬂow cytometry was signiﬁcant for expanded myeloid
blast population with 19% of the cells. Subsequent bone
marrow biopsy conﬁrmed acute myeloid leukemia with 62%
blasts by ﬂow cytometry in a hypercellular marrow with
markedly decreased background hematopoiesis. Immunophenotype showed blasts expressing CD34, CD117, partial
CD13, dim CD33, HLA-DR, CD7, CD38, and moderate to
dim CD45. Bone marrow aspirate smear is shown in Figure 2.
Molecular testing for NPM1 and FLT3 was negative. FISH
panel was positive for t(11q23) and gain of 3′KMT2A, diagnosing him with poor-risk mixed leukemia lineage- (MLL-)
associated AML.
A dedicated cardiac MRI (Figure 3) demonstrated evidence of nonischaemic myocardial inﬂammation consistent
with myocarditis. It also demonstrated multiple areas of late
subepicardial gadolinium enhancement in the lateral wall
and midmyocardial enhancement in the septum. Of note,
the MRI showed a normal ejection fraction and no associated pericardial eﬀusion. CMV PCR, coxsackie viral PCR,
adenovirus PCR, Lyme serology, anaplasmosis serology,
ehrlichiosis serology, mycoplasma PCR, inﬂuenza A and B
testing, COVID-19 PCR, HIV screen, and hepatitis testing
were negative. Furthermore, syphilis RPR, ANA, ANCA,
and blood and urine cultures were also negative. With these
negative tests, a presumptive diagnosis of AML-related
myocarditis was made via exclusion. A biopsy of the patient’s skin lesions was then performed, revealing for a
“dense dermal inﬁltrate of polymorphonuclear cells in a
pattern that would ﬁt best with a neutrophilic dermatosis,”
qualifying a ﬁnal diagnosis of sweet syndrome. The histologic image of the skin biopsy at both low and high magniﬁcation is shown in Figure 4.
The patient was started on “7 + 3” induction chemotherapy with seven days of cytarabine dosed at 100 mg/m2
daily and three days of daunorubicin dosed at 60 mg/m2
daily. The patient had complete resolution of his chest pain
shortly thereafter and marked improvement in his skin
lesions. His day 14 postinduction bone marrow biopsy
showed 60% cellularity with 50% blasts consistent with prior
leukemic blasts by ﬂow cytometry. Due to persistent presence of leukemia, he was started on high-dose cytarabine
(HiDAC) reinduction chemotherapy. After HIDAC, the
patient had count recovery, and bone marrow biopsy at that
time revealed no evidence of acute myeloid leukemia;
therefore, he was determined to have complete response. He
was discharged from the hospital seven weeks after his
admission date. At the time of discharge, his skin lesions had
healed to a signiﬁcant extent.

3. Discussion
Acute myeloid leukemia has a highly variable clinical presentation with rare associations documented. AML-related
myocarditis is one such poorly studied disease entity. In
general, myocarditis is a disease secondary to inﬂammation
of the cardiac muscle and has a nonspeciﬁc clinical presentation that ranges from acute chest pain to new onset
heart failure to cardiogenic shock, among others. Diagnosis
of clinically suspected myocarditis is based on a combination
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Figure 1: EKG performed in the ED showed a heart rate of 74 and a regular sinus rhythm, with no acute disease processes.

Figure 2: Bone marrow aspirate smears were signiﬁcant for approximately 62% myeloblasts, and the background hematopoiesis was
markedly decreased.

(a)

(b)

Figure 3: Continued.
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(c)

(d)

Figure 3: Cardiac MRI showed features consistent with myocarditis satisfying the updated Lake Louise criteria [4], visualized in these
images. (a) Mid-short-axis native T1 mapping demonstrated elevated native myocardial T1 at 1173 ms (local lab normal reference:
950–1050 ms). (b) Mid-short-axis T2 mapping demonstrated elevated myocardial T2 at 58 ms (normal reference: 40–50 ms). (c) Mid-shortaxis phase-sensitive inversion recovery late gadolinium enhancement image showed multiple areas of subepicardial enhancement in the
lateral wall, as well as midmyocardial enhancement in the septum. (d) Four-chamber late gadolinium enhancement image demonstrated
midmyocardial enhancement in the septum and subepicardial to midmyocardial enhancement in the lateral wall.

(a)

(b)

Figure 4: Skin biopsy showed dense dermal inﬁltrate of polymorphonuclear cells at both low (a) and high (b) magniﬁcation.

of the clinical presentation and diagnostic ﬁndings, which
can include characteristic tissue imaging on cardiac MRI [5].
This diagnosis via cardiac MRI is established via the updated
Lake Louise criteria where both of the following criteria
must be met: demonstration of edema, with regional or
global myocardial signal intensity increase in T2-weighted
images or with prolonged T2 relaxation times on native T2
mapping, as well as late gadolinium enhancement in a
nonischaemic distribution on inversion recovery-prepared
gadolinium-enhanced T1-weighted images [4]. Often, coronary arterial disease has to be ruled out via angiography. Of
course, gold standard diagnosis of myocarditis is based on
endomyocardial biopsy [6]. Inﬁltration of the heart muscle
by malignant leukemia cells is a known sequela of AML, but
this process is usually subclinical for unknown reasons [3].
Of 420 autopsies of myelogenous or lymphocytic leukemia
patients evaluated by Roberts et al., 288 (69%) of patients
had some degree of leukemic involvement of the heart. 190
of these patients had pericardial involvement, which was the

most common cardiac site of involvement [3]. AML with an
initial presentation of pericarditis is estimated to occur in 12% of cases. Myocarditis, however, is less frequently
documented. In our literature review, we identiﬁed only
three previous case reports documenting AML-related
myocarditis, which are described in Table 1 [7–9]. Of note,
pericarditis was also present in two of the three cases.
Furthermore, two of the three patients had cardiac MRI with
characteristic ﬁndings, and all three patients had negative
coronary artery angiography.
In contrast, acute myeloid leukemia is associated with
dermatologic involvement more commonly, with presence
in about 10% of new cases. These skin lesions include erythematous nodules, papules, or plaques, among others
[10, 11]. One of these dermatologic associations is an entity
known as sweet syndrome. The classical form of sweet
syndrome, also known as neutrophilic dermatosis, is a rare
disorder consisting of fever, neutrophilia, and tender erythematous skin lesions characterized by mature neutrophils
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Table 1: Myocarditis/myopericarditis in AML patients.

Age/sex

37/F

48/M

62/M

Presentation
Cardiac evaluation
Leukemic evaluation
Treatment
Myopericarditis: colchicine
Acute exertional chest pain
and NSAIDs.
with radiation to arms.
ECG with ST elevations in Negative coronary artery
leads I, aVL, V1, and V2
angiography. TTE: EF of
and PR elevation in lead 50–55% with hypokinetic
AML “conﬁrmed on bone
AVR. Troponin elevated at
right ventricle. Cardiac
marrow biopsy.”
1.6 ng/mL.
AML treatment not stated.
MRI: EF of 33% with signal
CBC showed WBC of
changes consistent with
13.7 k/µL with 28% blasts,
myocarditis.
Hgb of 10.0 g/dL, and Plts
145 k/µL.
Myopericarditis: colchicine
Acute substernal chest
0.6 mg BID; ibuprofen
°
pain. Febrile (103.4 F).
600 mg TID
ECG with ST segment
Bone marrow biopsy:
Negative coronary artery
elevation in leads I, II, aVL,
hypercellular marrow with
angiography with an
and V5 with PR elevation
diﬀuse mononuclear
ejection fraction of 40–45%.
and ST depression in aVR.
inﬁltrates with ﬂow
There was mild hypokinesis
Troponin-I was 14.8 ng/
AML: 7 d cytarabine and
in the midinferior and mid- cytometry consistent with
mL. CBC revealed
3 d idarubicin followed by
AML. FISH analysis was
anterolateral walls and no
hemoglobin of 10.8 g/dL,
salvage therapy with
positive for t(6; 9) (p23;
pericardial eﬀusions. TTE
white cell count of 13,000/
HIDAC and midostaurin.
q34).
revealed the same ﬁndings.
µL, 56% blasts, absolute
neutrophil count of 1,430/
µL, and platelet count of
83 × 103/µL.
TTE: normal biventricular
function with inferolateral
Myocarditis: antihypokinesia. Angiography:
inﬂammatory therapy.
Acute chest pain. ECG
normal coronary arteries. Bone marrow biopsy: 47%
with ST elevation in
Cardiac MRI: cardiac
blasts suggestive for AML.
inferior leads. Troponin of
dysfunction with areas of
AML: ﬂudarabine, steroids,
1.5 µg/L.
myocardial edema and late
and cytarabine.
enhancement.

Author

Snavely
et al. [7]

Agrawal
et al. [8]

De
Lazzari
et al. [9]

AML: acute myeloid leukemia; CBC: complete blood count; ECG: electrocardiogram; EF: ejection fraction; FISH: ﬂuorescence in situ hybridization; Hgb:
hemoglobin; HIDAC: high-dose cytarabine; Plts: platelets; TTE: transthoracic echocardiogram; WBC: white blood cells.

in the upper dermis [12]. Numerous precipitating factors
have been identiﬁed, including inﬂammatory bowel disease,
pregnancy, and administration of drugs such as G-CSF,
among others. Sweet syndrome cases are very often associated with malignancy, with AML being the most common
oﬀender. Malignancy-associated sweet syndrome has been
documented on numerous occasions to be the presenting
symptom of previously undiagnosed neoplastic process;
however, it can also occur as a paraneoplastic process in a
patient with an already established diagnosis of malignancy.
The exact pathogenesis of sweet syndrome is not fully understood; various proposed mechanisms have included an
exaggerated hypersensitivity reaction, heritable mutations
predisposing to the illness, and dysregulated cytokine (especially G-CSF) production. The lesions classically appear in
multiple locations on the body, with one study suggesting
that the upper and lower extremities and trunk were most
commonly aﬀected [13]. This study also found that a majority of the lesions were erythematous, with plaques being
the most common morphology, but with vesicles or pustules
being a known variant of the disease, appearing just under

20% of the time. The lesions were tender to palpation in 43%
of cases and pruritic in 18% of cases. The gold standard for
diagnosis is a biopsy showing the characteristic diﬀuse inﬁltration by mature neutrophils. First-line treatment is
systemic corticosteroids, which typically cause immediate
improvement in symptoms, with subsequent resolution of
skin lesions [13]. Treatment of the underlying cause, if
identiﬁed, is also indicated.
Our patient’s presentation was consistent with malignancy-associated sweet syndrome in several ways. The
papular lesions were tender, erythematous, and characteristically distributed on his lower and upper extremities. His
previously undiagnosed AML is the most common malignancy associated with sweet syndrome. A skin biopsy ultimately conﬁrmed the disease, and his rash improved with
treatment of his malignancy. This patient’s concurrent
myocarditis diagnosis was established with cardiac MRI
using the updated Lake Louise criteria [4]. His myocarditis
was likely related to his diagnosis of sweet syndrome due to
exclusion of other etiologies and occurring in the setting of
both sweet syndrome rash and acute leukemia, two known
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Table 2: Cases of sweet syndrome with concurrent myocarditis.

Age/sex

40/F

64/F

41/M

42/M

Factors supporting
Factors supporting
diagnosis of sweet
diagnosis of
Therapy administered
syndrome
myocarditis
Edematous and
erythematous plaques
Fever, acute
with some central
shortness of breath,
blistering and erosions,
and chest pain.
located on the arm,
neck, and palate.
Topical clobetasol cream, 6
Troponin T 0.12 ng/
weeks of
mL (elevated) and
Mesalamine
indomethacin + colchicine,
CRP 184 mg/L
(drug induced)
Biopsy: inﬂammatory
and mesalamine
(elevated).
inﬁltrate of the dermis,
discontinued
ECG: diﬀuse ST
consisting of
elevations.
neutrophils and
Cardiac MRI:
leukocytoclasis.
diﬀuse pericardial
enhancement and
edema.
Clinically, the
patient had
symptoms
consistent with
Movable, tender,
myocarditis.
erythematous,
Cardiac MRI: a
cutaneous nodule of
small amount of
1.5 cm × 1.5 cm at the
Myelodysplastic
inner aspect of the right pericardial eﬀusion
Prednisolone 30 mg/day
syndrome
lower leg. Skin biopsy and slightly dilated
LA. Postmortem
demonstrated acute
heart biopsy:
febrile neutrophilic
perivascular and
dermatosis.
myocardial
neutrophil
inﬁltration.
Painful erythematous EKG changes and
papules and plaques on elevated cardiac
biomarkers.
the nape, neck,
shoulders, and arms, as
well as painful
hyperpigmented
Cardiac MRI:
Oral prednisolone 1 mg/kg/
subcutaneous nodules.
patchy
Idiopathic
day
Skin biopsy:
subepicardial
subepithelial edema,
enhancement and
dermal inﬂammatory
slight edema in the
inﬁltrate with
inferolateral wall.
polymorphonuclear
predominance and
absence of vasculitis.
Myocardial biopsy
revealed interstitial
edema and
“New skin lesions
perivascular
compatible with sweet
neutrophil inﬁltrate.
syndrome
Hydrocortisone 1 mg/kg/day,
Additionally, an
G-CSF
reactivation.” Sweet
with noninvasive ventilation
echocardiogram
administration
syndrome had
and IV diuretics
with new LV
previously been
conﬁrmed on biopsy in systolic dysfunction
and CXR with
an episode 1 year prior.
enlarged cardiac
silhouette.
Suspected
etiology

CXR: chest X-ray; CRP: C-reactive protein; ECG: electrocardiogram; LA: left atrium; LV: left ventricle.

Outcome

Author

Resolution of
myopericarditis
Shabtaie
within 20 days; no
et al. [14]
skin lesions at 6
weeks of follow-up

Death secondary
to sudden cardiac
arrest 3 days after
presentation

Shimizu
[15]

Complete
resolution of
Graçasymptoms within
Santos
4 days of
et al. [16]
presentation

Clinical
parameters,
invasive
monitoring values, Dı́az et al.
and ventricular
[17]
function
normalized at 48
hours
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associations. The treating physicians still decided to treat
with an anthracycline-based induction chemotherapy regimen despite the ﬁnding of myocarditis. This was because the
patient still had preserved heart function, was hemodynamically stable, and was of young age with few comorbidities and thus would most beneﬁt from high-intensity
induction chemotherapy. Fortunately, his chest pain never
recurred after treatment of his leukemia. Cases in the literature regarding the combination of sweet syndrome and
myocarditis are described in Table 2 [14–17]. All four patients were treated for their sweet syndrome with some form
of steroid administration. Three of the four had complete
recovery from their disease; however, the fourth died due to
cardiac arrest shortly after presentation. Of signiﬁcance,
there are no reported cases of sweet syndrome with concurrent myocarditis as symptoms of acute myeloid leukemia.
In conclusion, this patient had biopsy-proven neutrophilic dermatosis and subacute myocarditis as presenting
symptoms of acute myeloid leukemia, supporting a diagnosis of sweet syndrome. Providers should be aware of this
clinical syndrome, especially because it may be the ﬁrst
manifestation of underlying hematologic malignancy.

Data Availability
The literature review data used to support the ﬁndings of this
study are included within the article.
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